

SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

-----  
FORM S-8  
REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

-----  
CRYO-CELL INTERNATIONAL, INC.  
(Exact name of registrant as specified in its charter)

-----  
DELAWARE  
-----  
(State or other jurisdiction of  
incorporation or organization)

22-302-3093  
-----  
(I.R.S. Employer Identification No.)

-----  
Daniel Richard, Chief Executive Officer  
604 Packard Court  
Safety Harbor, FL 34695  
(813) 938-3114  
(Address of Registrant's principal executive offices, including zip code)

-----  
ADVISOR COMPENSATION PLAN  
(Full title of the Plan)

Mark Richard, Esquire  
304 Palermo Avenue  
Coral Gables, FL 33134  
(305) 443-5125  
(Name, address and telephone number of agent for service)

-----  
COPIES TO:  
Lawrence W. Horwitz, Esq.  
Horwitz & Beam  
Two Venture Plaza, Suite 380  
Irvine, CA 92718

-----  
Approximate Date of Proposed Sale to the Public:  
As soon as practicable after this Registration Statement becomes effective.

<TABLE>  
<CAPTION>

-----  
CALCULATION OF REGISTRATION FEE

TITLE OF SECURITIES TO BE REGISTERED	AMOUNT TO BE REGISTERED	PROPOSED MAXIMUM OFFERING PRICE PER SHARE	PROPOSED MAXIMUM AGGREGATE OFFERING PRICE	AMOUNT OF REGISTRATION FEE
<S> Common Stock, \$0.01 Par Value(1)	<C> 10,000(1)	<C> \$4.0000(2)	<C> \$40,000	<C> \$12.12

<FN>  
-----  
(1) Includes 10,000 shares of common stock, issuable for counseling and advisory services to Horwitz & Beam.

(2) The registration fee is based upon the exercise price of the options at \$4.00 per share calculated pursuant to Rule 457.

</FN>  
</TABLE>

<TABLE>  
<CAPTION>

CRYO-CELL INTERNATIONAL, INC.

CROSS REFERENCE SHEET REQUIRED BY ITEM 501(b) OF REGULATION S-K

FORM S-8 ITEM NUMBER AND CAPTION	CAPTION IN PROSPECTUS
<S> -----	<C> -----

1. Forepart of Registration Statement and Outside Front Cover Page of Prospectus	Facing Page of Registration Statement and Cover Page of Prospectus
2. Inside Front and Outside Back Cover Pages of Prospectus	Inside Cover Page of Prospectus and Outside Cover Page of Prospectus
3. Summary Information, Risk Factors and Ratio of Earnings to Fixed Charges	Not Applicable
4. Use of Proceeds	Not Applicable
5. Determination of Offering Price	Not Applicable
6. Dilution	Not Applicable
7. Selling Security Holders	Sales by Selling Security Holder
8. Plan of Distribution	Cover Page of Prospectus and Sales by Selling Security Holder
9. Description of Securities to be Registered	Description of Securities;
10. Interests of Named Experts and Counsel	Legal Matters
11. Material Changes	Not Applicable
12. Incorporation of Certain Information by Reference	Incorporation of Certain Documents by Reference
13. Disclosure of Commission Position on Indemnification for Securities Act Liabilities	Indemnification of Directors and Officers; Undertakings

</TABLE>

DATED: May 9, 1997

## PART II

### Item 3. INCORPORATION OF DOCUMENTS BY REFERENCE.

The Registrant incorporates the following documents by reference in the registration statement:

The Company's Annual Report on Form 10-KSB filed for the year ended November 30, 1996 and the Company's Quarterly Report on Form 10-QSB for the quarter ended February 29, 1997; and description of the Company's Common Stock contained in the Company's Form 8-A dated February 4, 1994.

All other documents filed in the future by Registrant after the date of this Registration Statement, under Section 13(a), 13(c), 14 and 15(d) of the Securities Exchange Act of 1934, prior to the filing of a post-effective amendment to this Registration Statement which deregisters the securities covered hereunder which remain unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be a part hereof from the date of filing of such documents.

### Item 4. DESCRIPTION OF SECURITIES.

The class of securities to be offered is registered under Section 12(g) of the Securities Exchange Act of 1934, as amended. A description of the Registrant's securities is set forth in the Prospectus incorporated as a part of this Registration Statement.

### Item 5. INTERESTS OF NAMED EXPERTS AND COUNSEL

None.

### Item 6. INDEMNIFICATION OF OFFICERS AND DIRECTORS

The Company's Bylaws and the Delaware General Corporation Law provide for indemnification of directors and officers against certain liabilities. Officers and directors of the Company are indemnified generally against expenses actually and reasonably incurred in connection with proceedings, whether civil or criminal, provided that it is determined that they acted in good faith, were not found guilty, and, in any criminal matter, had reasonable cause to believe that their conduct was not unlawful.

The Company's Certificate of Incorporation further provides that a director of the Company shall not be personally liable for monetary damages to the Company or its shareholders for breach of any fiduciary duty as a director, except for liability (i) for any breach of the director's duty of loyalty to the

Company or its stockholders; (ii) for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law; (iii) for the unlawful payments of dividends or stock redemption by the Company or (iv) for any transaction from which the director derives an improper personal benefit.

Item 7. EXEMPTION FROM REGISTRATION CLAIMED

Not applicable.

Item 8. EXHIBITS

4 Retainer Agreement with Horwitz & Beam.

5 Opinion of Horwitz & Beam, consent included, relating to the issuance of the shares of securities pursuant to the Retainer Agreement.

23.1 Consent of Horwitz & Beam.

23.2 Consent of Mirsky, Furst & Associates, P.A.

Item 9. UNDERTAKINGS

(a) The undersigned registrant hereby undertakes:

(1) To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

(i) To include any prospectus required by section 10(a)(3) of the Securities Act of 1933;

(ii) To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement;

(iii) To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement, including (but not limited to) any addition or election of a managing underwriter.

(2) That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities offered at that time shall be deemed to be the initial bona fide offering thereof.

(3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

(b) The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act of 1933, each filing of the registrant's annual report pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of an employee benefit plan's annual report pursuant to Section 15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

(c) Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel that matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue.

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all



LAW OFFICES OF  
HORWITZ & BEAM  
TWO VENTURE PLAZA  
SUITE 380  
IRVINE, CALIFORNIA 92618  
(714) 453-0300  
(310) 842-8574  
FAX: (714) 453-9416

Lawrence W. Horwitz, Esq.  
Gregory B. Beam, Esq.  
Lawrence R. Bujold, Esq.  
Lawrence M. Cron, Esq.  
Lynne Bolduc, Esq.  
Thomas B. Griffen, Esq.  
John J. Isaza, Esq.  
Malea M. Farsai, Esq.

June 4, 1996

Mr. Daniel Richard  
Cryo-Cell International, Inc.  
8900 Grand Ave.  
Baldwin, New York 11510

VIA FACSIMILE

RE: LEGAL REPRESENTATION

Dear Mr. Richard:

This is to confirm our understanding whereby you have engaged this firm to represent you with respect to the proposed litigation against the University of Arizona and other defendants (hereinafter referred to as the "Matter"). This agreement only pertains to our representation in connection with the Matter. This letter, when signed by you, will constitute the written fee contract required by California law. In connection therewith, our understanding and agreement are as follows:

1. We will undertake to advise you in connection with the Matter and any other matters you ask us to undertake. We will undertake to prepare such documents as may be required to affect the foregoing.
2. There can be no assurances, and we make no guarantees, representations or warranties as to the particular results from our services and the response and timeliness of action by any governmental official or department.
3. You understand that the accuracy and completeness of any document prepared by us is dependent upon your alertness to assure that it contains all material facts which might be important and that such documents must not contain any misrepresentation of a material fact nor omit information necessary to make the statements therein not misleading. To that end, you agree to review, and confirm to us in writing that you have reviewed, all materials for their accuracy and completeness prior to any use thereof. You also acknowledge that this

responsibility continues in the event that the materials become deficient in this regard.

4. We will undertake the representation in connection with the matter in accordance with the following terms:

(a) 16.5% of the aggregate recovery up to the day prior to the commencement of the Mandatory Settlement Conference; this amount shall increase to 20% upon commencement of the Mandatory Settlement Conference; plus

(b) \$100 per hour payable in the form of stock as follows. We will bill you on a monthly basis. You will have 10 days from receipt of this bill to pay it in full, in cash. In the event you do not make such a payment, then we will be obligated to convert the amount owed into free-trading shares issued by Cryo-Cell., Inc pursuant to an S-8 registration statement as free trading shares ( the "Compensation Shares"). This amount shall include all attorney's fees and costs contained in our bill. Such conversion shall be at the average closing bid-price during the last 10 trading days for the calendar month during which we present our bill (the "Purchase Price") (ie. if our bill is dated July 17, then it would be the last 10 trading days in July). We agree to not trade any of the Compensation Shares during the 90-day period of time (the "Lock-Up Period") following the date of the bill giving rise to the right to receive the Compensation Shares. Upon the day which constitutes the final day of the Lock-Up Period you shall have an option to acquire for cash any or all of the Compensation Shares at the Purchase Price (the "Option"). In the event the

Option is not exercised with the payment of such cash, we will have the right to trade the Compensation Shares on the public securities markets. We may only receive up to \$250,000 in Compensation Shares as a result of our representation in connection with the Matter. In the event our firm is retained in connection with other litigation arising from the facts of the Matter, then any fees received by our firm shall be used to mitigate the amount owed by Cryo-Cell under this paragraph.

We will bill you monthly with the understanding that, except as set forth otherwise herein, unless otherwise agreed to by us, you will pay the full amount of each statement within ten days after your receipt thereof. Amounts past due for 30 days or more will be charged a finance charge of 10% per annum.

5. Except as set forth above, fees do not include incidental costs and expenses such as copying charges, long distance telephone charges, messenger charges, filing fees, court costs and facsimile charges. The other costs will be billed to you or, in the case of certain expenses such as corporate filing costs, you will be requested to provide such amounts in advance. You agree to pay all expenses advanced by the firm and to provide expenses in advance to the extent requested by the firm.

6. With respect to any new matters, hourly fees do not include incidental costs and expenses such as copying charges, long distance telephone charges, messenger charges, and facsimile charges. These costs will be billed to you on a monthly basis. You agree to pay all expenses advanced by the firm and to provide expenses in advance to the extent requested by the firm.

7. The firm reserves the right to immediately withdraw its representation in the event that (i) we discover any misrepresentation of information provided to us, or (ii) you and any of your affiliates engage in any conduct or activities contrary to our advice which in our

Mr. Daniel Richard  
June 4, 1996  
Page 8

opinion would constitute a violation of applicable law. In the event legal action is required to collect any amounts due hereunder, you agree to pay legal fees and expenses required to collect such amounts.

8. We will consult with you on all major decisions and will attempt to keep you fully informed of the status of the preparation of documents and responses to filings, if any, as well as our recommended strategies. You should feel free to call at any time if you have any questions or wish to discuss any aspect of this matter.

9. You are advised that the Firm maintains errors and omissions insurance coverage applicable to the services to be rendered.

10. This Agreement shall be governed by the laws of the State of California and venue for any action hereunder shall be in Orange County, California.

If this letter correctly sets forth your understanding and agreement with respect to the matters mentioned above, please execute and return one copy of this letter.

Very truly yours,

HORWITZ & BEAM

/s/ LAWRENCE HORWITZ

\_\_\_\_\_  
Lawrence W. Horwitz

The undersigned hereby confirms and agrees that this letter, executed and effective this 4th day of June, 1996, sets forth my understanding and agreement.

CRYO-CELL INTERNATIONAL, INC.

By: /s/ DANIEL D. RICHARD

\_\_\_\_\_  
Title: CHAIRMAN AND CEO

SSN: \_\_\_\_\_

EXHIBIT 5  
OPINION OF HORWITZ & BEAM

LAW OFFICES OF  
HORWITZ & BEAM  
TWO VENTURE PLAZA  
SUITE 380  
IRVINE, CALIFORNIA 92618  
(714) 453-0300  
(310) 842-8574  
FAX: (714) 453-9416

Gregory B. Beam, Esq.  
Lawrence W. Horwitz, Esq.  
Lawrence R. Bujold, Esq.  
Lawrence M. Cron, Esq.  
Lynne Bolduc, Esq.  
Thomas B. Griffen, Esq.  
John J. Isaza, Esq.  
Malea M. Farsai, Esq.

April 21, 1997

Securities and Exchange Commission  
450 Fifth Street, N.W.  
Judiciary Plaza  
Washington, DC 20549

Re: CRYO-CELL INTERNATIONAL, INC.

Ladies and Gentlemen:

This office represents CRYO-CELL INTERNATIONAL, INC., a Nevada corporation (the "Registrant") in connection with the Registrant's Registration Statement on Form S-8 under the Securities Act of 1933 (the "Registration Statement"), which relates to the registration of a total of 10,000 shares of the Registrant's Common Stock issuable upon exercise of options issued to Horwitz & Beam for performance of certain legal representation, advisory, and counseling services (the "Registered Securities"). In connection with our representation, we have examined such documents and undertaken such further inquiry as we consider necessary for rendering the opinion hereinafter set forth.

Based upon the foregoing, it is our opinion that the Registered Securities, when sold as set forth in the Registration Statement, will be legally issued, fully paid and nonassessable.

We acknowledge that we are referred to under the heading "Legal Matters" in the Prospectus which is a part of the Registrant's Form S-8 Registration Statement relating to the Registered Securities, and we hereby consent to such use of our name in such Registration Statement and to the filing of this opinion as Exhibit 5 to the Registration Statement and with such state regulatory agencies in such states as may require such filing in connection with the registration of the Registered Securities for offer and sale in such states.

HORWITZ & BEAM

EXHIBIT 23.1  
CONSENT OF HORWITZ & BEAM

CONSENT OF HORWITZ & BEAM

We hereby consent to the use in the Prospectus constituting part of the Registration Statement on Form S-8 of our opinion dated April 21, 1997 relating to the registration of the Securities, as therein defined, of CRYO-CELL INTERNATIONAL, INC., a Delaware corporation, which is attached as Exhibit 5 therein.

Dated: April 21, 1997

HORWITZ & BEAM, INC.,  
a California corporation

By: /s/ LAWRENCE W. HORWITZ  
-----  
Lawrence W. Horwitz  
Its: Vice President



EXHIBIT 23.2  
CONSENT OF MIRSKY, FURST & ASSOCIATES, P.A.

MIRSKY, FURST & ASSOCIATES, P.A.

CERTIFIED PUBLIC ACCOUNTANTS

201 MAIN STREET

FORT LEE, NEW JERSEY 07024  
-----

ROBERT MIRSKY, C P A	(201) 947-2186
MARVIN FURST, C P A	(212) 889-3410
ALAN P. KURINOVICH, C P A	FAX (201) 947-6629

TO: Board of Directors  
CRYO-CELL International, Inc.  
604 Packard Court  
Safety Harbor, Florida 34695

RE: Consent to Use Opinion

We hereby consent to the use of our opinion (dated February 3, 1996 from the Form 10-KSB for the fiscal year end November 30, 1996) as herein described.

This consent is in connection with the registration under the Securities Act of 1993; as amended, of 10,000 shares of your Common Stock issued pursuant to options which have been granted under Agreements for Counseling and Advisory Services.

MIRSKY, FURST & ASSOCIATES, P.A.

Fort Lee, New Jersey  
April 22, 1997